PROCEPT BioRobotics Corporation Cost of Revenue
PROCEPT BioRobotics Corporation (PRCT) reported Cost of Revenue of $32.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-05
- PROCEPT BioRobotics Corporation cost of revenue for the quarter ending 2026-06-30 was $32.12M, a 17.07% increase year-over-year.
- PROCEPT BioRobotics Corporation cost of revenue for the quarter ending 2026-03-31 was $29.18M, a 16.74% increase year-over-year.
- PROCEPT BioRobotics Corporation cost of revenue for the quarter ending 2025-12-31 was $30.07M, a 22.41% increase year-over-year.
- PROCEPT BioRobotics Corporation cost of revenue for the quarter ending 2025-09-30 was $29.32M, a 36.64% increase year-over-year.
- PROCEPT BioRobotics Corporation cost of revenue for fiscal 2025 was $111.83M, a 27.95% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation cost of revenue for fiscal 2024 was $87.40M, a 34.17% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation cost of revenue for fiscal 2023 was $65.14M, a 71.75% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation cost of revenue for fiscal 2022 was $37.93M, a 103.83% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.12M 10-Q · filed 2026-08-05 | $61.30M 10-Q · filed 2026-08-05 | $91.37M derived: sum of 3 quarters · filed 2026-08-05 | $120.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $29.18M 10-Q · filed 2026-04-30 | $59.26M derived: sum of 2 quarters · filed 2026-04-30 | $88.58M derived: sum of 3 quarters · filed 2026-04-30 | $116.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.39M derived: sum of 2 quarters · filed 2026-02-26 | $86.83M derived: sum of 3 quarters · filed 2026-08-05 | $111.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.32M 10-Q · filed 2025-11-05 | $56.76M derived: sum of 2 quarters · filed 2026-08-05 | $81.76M 10-Q · filed 2025-11-05 | $106.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $27.44M 10-Q · filed 2026-08-05 | $52.44M 10-Q · filed 2026-08-05 | $77.00M derived: sum of 3 quarters · filed 2026-08-05 | $98.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $25.00M 10-Q · filed 2026-04-30 | $49.56M derived: sum of 2 quarters · filed 2026-04-30 | $71.02M derived: sum of 3 quarters · filed 2026-04-30 | $92.89M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $24.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.02M derived: sum of 2 quarters · filed 2026-02-26 | $67.89M derived: sum of 3 quarters · filed 2026-02-26 | $87.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $21.46M 10-Q · filed 2025-11-05 | $43.33M derived: sum of 2 quarters · filed 2025-11-05 | $62.84M 10-Q · filed 2025-11-05 | $85.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $21.87M 10-Q · filed 2025-08-07 | $41.38M 10-Q · filed 2025-08-07 | $63.70M derived: sum of 3 quarters · filed 2026-02-26 | $79.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $19.50M 10-Q · filed 2025-05-02 | $41.83M derived: sum of 2 quarters · filed 2026-02-26 | $58.06M derived: sum of 3 quarters · filed 2026-02-26 | $72.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $22.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.55M derived: sum of 2 quarters · filed 2026-02-26 | $53.23M derived: sum of 3 quarters · filed 2026-02-26 | $65.14M 10-K · filed 2026-02-26 |
| 2023-09-30 | $16.23M 10-Q · filed 2024-10-28 | $30.90M derived: sum of 2 quarters · filed 2024-10-28 | $42.82M 10-Q · filed 2024-10-28 | $55.92M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.68M 10-Q · filed 2024-08-02 | $26.59M 10-Q · filed 2024-08-02 | $39.69M derived: sum of 3 quarters · filed 2025-02-27 | $49.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $11.91M 10-Q · filed 2024-05-02 | $25.01M derived: sum of 2 quarters · filed 2025-02-27 | $35.13M derived: sum of 3 quarters · filed 2025-02-27 | $43.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $23.22M derived: sum of 2 quarters · filed 2025-02-27 | $31.42M derived: sum of 3 quarters · filed 2025-02-27 | $37.93M 10-K · filed 2025-02-27 |
| 2022-09-30 | $10.12M 10-Q · filed 2023-11-02 | $18.32M derived: sum of 2 quarters · filed 2023-11-02 | $24.83M 10-Q · filed 2023-11-02 | $30.45M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $8.21M 10-Q · filed 2023-07-28 | $14.71M 10-Q · filed 2023-07-28 | $20.33M derived: sum of 3 quarters · filed 2024-02-28 | $24.76M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $6.50M 10-Q · filed 2023-05-04 | $12.13M derived: sum of 2 quarters · filed 2024-02-28 | $16.55M derived: sum of 3 quarters · filed 2024-02-28 | $21.45M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $10.05M derived: sum of 2 quarters · filed 2024-02-28 | $14.94M derived: sum of 3 quarters · filed 2024-02-28 | $18.61M 10-K · filed 2024-02-28 |
| 2021-09-30 | $4.43M 10-Q · filed 2022-11-04 | $9.32M derived: sum of 2 quarters · filed 2022-11-04 | $12.99M 10-Q · filed 2022-11-04 | $15.74M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $4.89M 10-Q · filed 2022-08-05 | $8.56M 10-Q · filed 2022-08-05 | $11.31M derived: sum of 3 quarters · filed 2022-08-05 | $13.45M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $3.67M 10-Q · filed 2022-05-06 | $6.42M derived: sum of 2 quarters · filed 2022-05-06 | $8.55M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $4.89M derived: sum of 2 quarters · filed 2022-03-22 | $8.97M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $2.14M 10-Q · filed 2021-11-05 | $6.22M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |